Mark McCorkindale, MD
Family Medicine · Wayne, NENPI 1679528616
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 302 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations.
Across 302 payments — averaging $12.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$900
- AbbVie$647
- Novo Nordisk$456
- Astellas Pharma US Inc$187
- Boehringer Ingelheim$182
- Novartis$162
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,921100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 84 | $900 |
| AbbVie(2 entities) | 60 | $647 |
| Novo Nordisk | 31 | $456 |
| Astellas Pharma US Inc | 11 | $187 |
| Boehringer Ingelheim | 13 | $182 |
| Novartis | 9 | $162 |
| Pfizer | 8 | $119 |
| Lilly USA, LLC | 8 | $101 |
| Merck | 7 | $97 |
| E.r. Squibb & Sons, L.L.C. | 6 | $88 |
| Bayer | 5 | $87 |
| Daiichi Sankyo Inc. | 6 | $85 |
| Biohaven Pharmaceuticals, Inc. | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $61 |
| Biogen | 4 | $59 |
| GSK | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| AstraZeneca | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Philips North America LLC | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Electromed, Inc. | 2 | $29 |
| Medtronic | 1 | $28 |
| Johnson & Johnson | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 2 | $25 |
| Alkermes, Inc. | 1 | $20 |
| Sanofi | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Rhythm Pharmaceuticals, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Organogenesis Inc. | 1 | $15 |
| Seqirus USA Inc | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
| Organon | 2 | $4 |
How this compares
$3,921 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 144 | $82,866 |
| MounjaroTirzepatide | 68 | $70,059 |
| Risperdal ConstaRisperidone Microspheres | 52 | $47,570 |
| TrulicityDulaglutide | 46 | $42,146 |
| MyrbetriqMirabegron | 84 | $40,685 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 83 | $24,512 |
| LinzessLinaclotide | 34 | $18,457 |
| FarxigaDapagliflozin Propanediol | 27 | $15,879 |
| JardianceEmpagliflozin | 25 | $15,707 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $15,142 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $13,634 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 54 | $11,094 |
| JanuviaSitagliptin Phosphate | 13 | $10,641 |
| Fondaparinux Sodium | 11 | $8,726 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $101 | $112,205114 claims |
| PfizerEliquis, Dilantin | $119 | $86,813165 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix, Breo Ellipta | $58 | $58,878179 claims |
| Johnson & JohnsonRisperdal Consta | $26 | $47,57052 claims |
| Astellas Pharma US IncMyrbetriq | $187 | $40,68584 claims |
| Boehringer IngelheimJardiance, Tradjenta | $182 | $21,96437 claims |
| AbbVieLinzess | $647 | $18,45734 claims |
| MerckJanuvia, Janumet | $97 | $17,40425 claims |
| AstraZenecaFarxiga | $44 | $15,87927 claims |
| BayerKerendia | $87 | $7,41412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Wayne
- Michael IsraelLincoln$375K
- Francisco DozonNorfolk$238K
- Randy KohlLincoln$67K
- James OmelGrand Island$67K
- Gerard StanleyOmaha$50K
- Jared KramerSt Paul$41K
- Randolph WaldmanHebron$27K
- Brian FinleyBellevue$20K
- William FitzgibbonsElkhorn$18K
- Michael BrennerSouth Sioux City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.